Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva +23 more
wiley +1 more source
Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. [PDF]
BACKGROUND: The screening of lead compounds against in vitro parasite cultures is an essential step in the development of novel anti-malarial drugs, but currently relies on laboratory parasite lines established in vitro during the last century.
Sutherland, CJ +18 more
core +1 more source
This review presents the structure and transport routes of the blood‐brain barrier, summarizes the ischemic stroke pathophysiological cascade, and discusses the BBB‐crossing mechanisms and multitarget therapeutic effects of carbon dots, demonstrating their promising theranostic potential for ischemic stroke.
Yanhan Huang +6 more
wiley +1 more source
Artemisinin-based combination therapy does not measurably reduce human infectiousness to vectors in a setting of intense malaria transmission [PDF]
<p>Background: Artemisinin-based combination therapy (ACT) for treating malaria has activity against immature gametocytes. In theory, this property may complement the effect of terminating otherwise lengthy malaria infections and reducing the ...
Huho, B. J. +62 more
core +2 more sources
Background Humanity has become largely dependent on artemisinin derivatives for both the treatment and control of malaria, with few alternatives available.
Rajeev K. Tyagi +8 more
doaj +1 more source
Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa
Artemisinin resistance has emerged and spread in the Greater Mekong Sub-region (GMS), followed by artemisinin-based combination therapy failure, due to both artemisinin and partner drug resistance.
Christian Nsanzabana
doaj +1 more source
Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer
The glucocorticoid receptor NR3C1 drives prostate cancer radioresistance by upregulating ACSL4. High ACSL4 levels create a lipid metabolic vulnerability. The clinical agent DHA synergizes with ACSL4 to induce lipid peroxidation and ferroptosis, effectively overcoming radioresistance.
Jing Yang +7 more
wiley +1 more source
Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. [PDF]
BACKGROUND: Most malaria-endemic countries are implementing a change in anti-malarial drug policy to artemisinin-based combination therapy (ACT). The impact of different drug choices and implementation strategies is uncertain.
Hastings, Ian M +26 more
core +1 more source
Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer
Background Anaplastic thyroid carcinoma is a highly lethal subtype of thyroid cancer without effective therapies. Drug resistance in anaplastic thyroid carcinoma poses a significant problem. Although artemisinin exerts antitumor effects, but its efficacy
Yitian Li
doaj +1 more source
PEG400 regulates Falcipain 2 activity through an allosteric mechanism
Falcipain‐2 can potentially be leveraged as a drug target due to its critical role as a haemoglobinase during the intra‐erythrocytic stage of Plasmodium falciparum. Here, we investigate the regulation of the proteolytic and haemoglobinase activity of falcipain‐2 in the presence of polyethylene glycol.
Bikram Nath +2 more
wiley +1 more source

